As a follow-up to our previous posting on the impact of FTY720 or Fingolimod on brain atrophy. Good news! After several months of logistical issues we finally randomised and dosed our first patients in the FTY720 PPMS trial.
“It is good to be able to finally offer our patients with primary progressive MS the possibility of being enrolled in a clinical trial. For once I don’t feel like a therapeutic nihilist when it comes to PPMS.”
CoI: Dr Klaus Schmierer is the PI at our site, I have received personal compensation for sitting on a steering committee for the phase 4 development of Fingolimod and we have received grant support for work on our animal model from Novartis who market Fingolimod.